All In Biotech

Drug Trial Radar · NCT06689514

Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jan 20, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Yifeng JingAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 55 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Benign prostatic hyperplasia (BPH) is one of the most common urinary and reproductive system diseases in elderly men. The preliminary research of the research group found that mast cells are cells that promote the progression of BPH, and the commonly used mast cell membrane stabilizer and TGF - β pathway inhibitor tranilast significantly inhibited the increase in prostate volume in animal experiments, which is considered to have potential applications in the treatment of BPH. This study plans to include 30 patients with medium to large volume BPH and experimentally explore the efficacy and safety of tranilast in the treatment of medium to large volume BPH.

Conditions

  • Prostatic Hypertrophy, Benign

Interventions

  • alpha receptor antagonistDrug

    Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)

  • Low dose TranilastDrug

    Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID

  • High dose TranilastDrug

    Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prostate volumeTime frame: The first month and the sixth month

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, China · Not yet recruiting

  • Shanghai General Hospital

    Shanghai, Outside U.S./Canada, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.